A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined With Chemotherapy as a First-line Treatment for Non-Small Cell Lung Cancer (KEYNOTE-782)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms KEYNOTE-782
- 17 Sep 2019 Planned End Date changed from 14 Jul 2021 to 31 Jan 2020.
- 13 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2019 Planned End Date changed from 4 Mar 2022 to 14 Jul 2021.